stockrowSol-Gel Technologies Ltd.
SLGLSol-Gel Technologies Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $19.4 million, up 68.0% from fiscal 2024.
- Revenue
- −96.6%
- EPS
- −127.1%
- Free cash flow
- −8.76%
Quarter to June 2026, against a year earlier
Follow SLGL
Alert me
Sol-Gel Technologies Ltd. (SLGL) Return on invested capital
Sol-Gel Technologies Ltd.'s return on invested capital over the twelve months to 30 June 2026 was −6,630.2%, down 6630.2 percentage points from fiscal 2025 (0.00%). Over the past ten years it has ranged from −1,090.0% (fiscal 2018) to 5.48% (fiscal 2021); the current reading is higher than 91% of that period. That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 0.00% | 152.12 |
| FY2024 | −152.1% | 19.70 |
| FY2023 | −171.8% | (123.67) |
| FY2022 | −48.2% | (53.63) |
| FY2021 | 5.48% | 91.08 |
| FY2020 | −85.6% | 691.53 |
| FY2019 | −777.1% | 312.91 |
| FY2018 | −1,090.0% | (830.41) |
| FY2017 | −259.6% | (259.63) |
| FY2016 | 0.00% | 0.00 |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| PLX Protalix BioTherapeutics, Inc. compare | 48.5% |
| PALI Palisade Bio, Inc. compare | 0.00% |
| RNAC Cartesian Therapeutics, Inc. compare | 0.00% |
| ARTV Artiva Biotherapeutics, Inc. compare | 0.00% |
| DRUG Bright Minds Biosciences Inc. compare | 0.00% |
| IKT Inhibikase Therapeutics, Inc. compare | 0.00% |
| ELDN Eledon Pharmaceuticals, Inc. compare | 0.00% |
| IFRX InflaRx N.V. compare | −87.3% |
| SLGL Sol-Gel Technologies Ltd. | −6,630.2% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)